Antiviral guanosine ribonucleoside analog; misincorporated into mRNA by viral-dependent RNA polymerases. Binds to and redistributes mammalian eIF4E from the nucleus to the cytoplasm (Ki
~ 0.3 μ
M for the active metabolite, ribavirin triphosphate). Represses colony formation of primary AML-M5 progenitor cells (IC50
~ 1 μ
M); reduces disease severity in acute myeloid leukemia (AML). Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.
Kentsis et al.
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
Assouline et al.